Cargando…

Interaction Between Determinants Governing Urine Volume in Patients With ADPKD on Tolvaptan and its Impact on Quality of Life

INTRODUCTION: Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic cause of kidney failure. Tolvaptan, a vasopressin 2 receptor antagonist, is the first drug with proven disease-modifying activity. Long-term treatment adherence is crucial, but a considerable fraction of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Todorova, Polina, Arjune, Sita, Hendrix, Claudia, Oehm, Simon, Schmidt, Johannes, Krauß, Denise, Burkert, Katharina, Burst, Volker Rolf, Benzing, Thomas, Boehm, Volker, Grundmann, Franziska, Müller, Roman-Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403673/ https://www.ncbi.nlm.nih.gov/pubmed/37547529 http://dx.doi.org/10.1016/j.ekir.2023.05.011

Ejemplares similares

Copeptin in autosomal dominant polycystic kidney disease: real-world experiences from a large prospective cohort study
por: Arjune, Sita, et al.
Publicado: (2023)

A Low-Cost Sequencing Platform for Rapid Genotyping in ADPKD and its Impact on Clinical Care
por: Lindemann, Christoph Heinrich, et al.
Publicado: (2022)

Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD—a randomized controlled trial
por: Cukoski, Sadrija, et al.
Publicado: (2023)

Tolvaptan in ADPKD Patients With Very Low Kidney Function
por: Torres, Vicente E., et al.
Publicado: (2021)

Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients
por: Bargagli, Matteo, et al.
Publicado: (2021)

Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD
por: Higashihara, Eiji, et al.
Publicado: (2021)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD
por: Zhou, Xiaolei, et al.
Publicado: (2022)

Effects of Tolvaptan on Oxidative Stress in ADPKD: A Molecular Biological Approach
por: Rigato, Matteo, et al.
Publicado: (2022)

A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD
por: Perrone, Ronald D., et al.
Publicado: (2020)

Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD
por: Mallett, Andrew J., et al.
Publicado: (2021)

Cyst Fraction as a Biomarker in Autosomal Dominant Polycystic Kidney Disease
por: Karner, Larina A., et al.
Publicado: (2022)

Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD
por: Makabe, Shiho, et al.
Publicado: (2021)

Author’s Reply to Correspondence: “Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients”
por: Heida, Judith E., et al.
Publicado: (2021)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022)

Preoperative Short‐Term Restriction of Sulfur‐Containing Amino Acid Intake for Prevention of Acute Kidney Injury After Cardiac Surgery: A Randomized, Controlled, Double‐Blind, Translational Trial
por: Osterholt, Thomas, et al.
Publicado: (2022)

The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
por: Tarabzuni, Ola
Publicado: (2022)

Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
por: Gkekas, Eleftherios, et al.
Publicado: (2022)

Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment
por: Barnawi, Rashid A, et al.
Publicado: (2018)

10-Year Evaluation of Adherence and Satisfaction with Information about Tolvaptan in ADPKD: A Single-Center Pilot Study
por: Schirutschke, Holger, et al.
Publicado: (2021)

A case report of recurrent membranoproliferative glomerulonephritis after kidney transplantation due to ventriculoatrial shunt infection
por: Völker, Linus A., et al.
Publicado: (2019)

Microvascular perfusion, perfused boundary region and glycocalyx shedding in patients with autosomal dominant polycystic kidney disease: results from the GlycoScore III study
por: Fuchs, Alexander, et al.
Publicado: (2022)

Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS
por: Osterholt, Thomas, et al.
Publicado: (2023)

Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)
por: Agraz-Pamplona, I., et al.
Publicado: (2020)

Dietary restriction for prevention of contrast-induced acute kidney injury in patients undergoing percutaneous coronary angiography: a randomized controlled trial
por: Grundmann, Franziska, et al.
Publicado: (2020)

Preoperative Short‐Term Calorie Restriction for Prevention of Acute Kidney Injury After Cardiac Surgery: A Randomized, Controlled, Open‐Label, Pilot Trial
por: Grundmann, Franziska, et al.
Publicado: (2018)

Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study
por: Burst, Volker, et al.
Publicado: (2017)

Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report
por: Pellegrino, Angela Maria, et al.
Publicado: (2019)

Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry
por: Aiello, Valeria, et al.
Publicado: (2021)

Heterogeneous Cardiovascular Profiles in CKD: ADPKD Versus non-ADPKD
por: Au, Eric H.K., et al.
Publicado: (2022)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model
por: Bennett, Hayley, et al.
Publicado: (2019)

Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria
por: Takagi, Koji, et al.
Publicado: (2017)

Preconditioning strategies to prevent acute kidney injury
por: Späth, Martin Richard, et al.
Publicado: (2020)

Rapid SARS-CoV-2 testing in primary material based on a novel multiplex RT-LAMP assay
por: Schermer, Bernhard, et al.
Publicado: (2020)

Antenatally Diagnosed ADPKD
por: Aldridge, Melanie, et al.
Publicado: (2018)

Intrafamilial Variability of ADPKD
por: Lanktree, Matthew B., et al.
Publicado: (2019)

Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment
por: Zittema, Debbie, et al.
Publicado: (2017)

Nephrologie
por: Burst, Volker
Publicado: (2010)

Modulation of Endocannabinoids by Caloric Restriction Is Conserved in Mice but Is Not Required for Protection from Acute Kidney Injury
por: Hoyer-Allo, Karla Johanna Ruth, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_05c8lh8jb1nu4thau5bnrml3ma